Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

NCT01613768 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Salivary Gland Cancer
Stage IVA Salivary Gland Cancer
Stage IVB Salivary Gland Cancer
Stage IVC Salivary Gland Cancer

Interventions

DRUG: eribulin mesylate

Sponsor

University of Washington

Collaborators

[object Object]